巴克莱将 Ionis 目标价上调至 106 美元

What happened: Barclays raised its price target for Ionis Pharmaceuticals (IONS) to $106, citing a projected $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia, with a PDUFA date of June 30, 2026. This follows Tryngolza generating $108 million in 2025 sales and a Q4 revenue beat. H.C. Wainwright also increased its price target to $130.

Market impact: The bullish sentiment around IONS has pushed up its stock price, benefiting investors who have bought in. The positive outlook for olezarsen's sales potential has driven interest in the company, potentially attracting more investors. The bearish view on Apellis Pharmaceuticals (APLS) by Cantor Fitzgerald, however, serves as a counterpoint, highlighting the mixed sentiment in the sector.

What to watch next: The FDA's decision on olezarsen's approval on June 30, 2026, will be a critical catalyst, as it could validate Barclays' and H.C. Wainwright's bullish price targets. Additionally, IONS' Q1 2023 earnings, expected in late April, will provide insights into the company's current financial health and progress. Lastly, any updates on Tryngolza's commercial performance could further influence IONS' stock price.